. The remainder of the tissue was snap frozen in liquid nitrogen and finally pulverised in a micro-dismembrator (Braun AG, Melsungen, Germany). The powdered tissue was then lyophilised to dryness and stored at -70°C until needed. For growth factor studies 70 mg of the lyophilised material was used whereas only 50 mg were required for steroid measurements.
Since the realisation that androgens are not alone in influencing the growth and regulation of the prostate, several investigations into the role of growth factors and their relationship with androgens have been undertaken. Initially, studies on the normal rat prostate demonstrated that the receptors for epidermal growth factor (EGF) were down regulated by androgens (Traish & Wotiz, 1987; St. Arnaud et al., 1988) . Subsequently experiments on androgen responsive prostate cancer cell lines revealed relatively low numbers of EGF receptors whilst androgen unresponsive cells expressed higher EGF receptor numbers (MacDonald & Habib, 1992) . The correlation between EGF receptor expression and endocrine status suggest that steroid hormones might influence the response to growth factors, by altering growth factor receptor expression, but this response may also reflect the species from which the prostate cells were derived. Receptors for EGF have also been identified in human benign hyperplastic prostate (BPH) but their concentrations were markedly depleted in the poorly differentiated prostate cancer (Maddy et al., 1989) . Significantly, this loss in EGF-receptor expres- sion is manifested at a time when the prostate tumour exhibits a reduced sensitivity to steroid hormones. It is not clear whether these two events are interrelated but the progression to an androgen independent state may, in part, be due to a reduced need for exogenous mitogens because of the the autologous production of growth factors (Sporn & Roberts, 1985) . Transforming growth factor alpha (TGFa) is a polypeptide growth factor which has been reported to modulate autocrine growth in several tumour systems Hofer et al., 1991; Lloyd et al., 1992; MacDonald et al., 1990) (Gleason, 1977) . The remainder of the tissue was snap frozen in liquid nitrogen and finally pulverised in a micro-dismembrator (Braun AG, Melsungen, Germany). The powdered tissue was then lyophilised to dryness and stored at -70°C until needed. For growth factor studies 70 mg of the lyophilised material was used whereas only 50 mg were required for steroid measurements.
Extraction of growth factors Lyophilised samples were resuspended in 1 ml buffer (50 mmol 1 Tris, 5 mol 1' of phenyl-methylsulphonyl fluoride, 2 mmol I 1' of EDTA pH 7.4) containing 1,000 counts of either '251I-EGF or '25I-TGFx to monitor manipulative losses. The samples were homogenised with a glass/glass Dounce Homogeniser and left on ice for 1 h to equilibrate. The homogenates were then centrifuged, the supernatants saved and the resultant pellets were resuspended in 2 ml of enzyme mixture (230 U ml-' of collagenase, 125 U ml-' of hyaluronidase in 150 mmol 1' of NaCI) and incubated overnight at 37C; these conditions were found to be optimal and ensured maximum growth factor recovery. The digested pellets were subsequently sonicated (six cycles of 20s with 1 min cooling interval at an amplitude of 22 ,; MSE soniprep 150) the resultant mixture was centrifuged as before, the supernatant saved and the pellet was resuspended in 2 ml Tris buffer. Homogenisation, centrifugation and resuspension were then repeated twice with the supernatants always being saved. The supernatants were then pooled and the recoveries were assessed. The mean recovery of '251I-EGF added at the beginning of the extraction procedure was 72 ± 6% whilst that of 125I-TGFo was 69 ± 8%. The. supernatants were finally snap frozen, lyophilised to dryness and stored at -700 until required.
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Radio-immunoassays for hEGF and hTGFc The concentrations of immunoreactive hEGF and hTGFa in the lyophilised samples were determined by a liquid phase competitive RIA. Briefly, the lyophilised material was reconstituted in 7001l of PBS (0.02 mol 1-of Na2HPO4.2H20, 0.02 mol 1 -' Na2HPO4.2H20, 0.9% NaCl, 3.7 g 1 -' of EDTA, I g l-of BSA, pH 7.4) and the assays were performed in triplicate employing 100 gil of the reconstituted lyophilised material. The radio immunoassay for hEGF was as described previously (MacDonald et al., 1990) . No cross reaction was found with transforming growth factor-a, which exerts all of its biological effects via the EGF receptor, up to concentrations of 1 fgml-'. Cross reactivity of this antiserum with a large variety of other substances has been tested by other investigators (Gregory et al., 1979; Jaspar et al., 1985) . TGFa content was analysed using a commercial kit (Peninsula Laboratory Europe Ltd, St Helens, Merseyside) with rTGF1 as radioiodinated tracer and hTGFa as reference standard. Antisera to the rTGF1 was raised in rabbits and purchased from Peninsula Laboratory Europe Ltd. The rabbit anti-rat TGF1 antisera recognises both mouse and hTGFa but does not crossreact with either mouse or hEGF.
Half maximal inhibition of binding of the 1251I-peptide to the antibody occurred at 140pg/tube.
Measurement of androgens
Specific radioimmunoassays for testosterone and dihydrotestosterone (DHT) were carried out after a single separation on Gelman ITLC plates using an antiserum against dihydrotestosterone (Guildhay Antisera Ltd, Guildford, Surrey). The extraction of the androgens from the tissue, chromatographic separation, radioimmunoassay and reliability of the method have already been described in detail (Habib et al., 1976; Houston et al., 1985) . Briefly 50 mg of the lyophilised powdered tissue extract was reconstituted in 2 ml of Tris HCI buffer containing 1,000 cpm radioactive steroids for each of the androgens to be assayed for recovery. Following equilibration, the steroids were extracted three times with diethylether and the pooled extracts were dried down, reconstituted in 50 gIl ethanol and separated on thin layer chromatography plates. The steroids were subsequently extracted, reconstituted in PBS buffer, recovery was assessed and the radioimmunoassay carried out.
Protein determination Protein was estimated by the method of Bradford (1976) using bovine serum albumin as standard.
Data analysis All analysis were performed in triplicate and the data has been presented as mean ± standard error of the mean. Differences in growth factors and androgen concentrations were tested for statistical significance by student t-test. Correlation of the degree of association for any two parameters was determined by calculation of the correlation co-efficient (r): r values presenting a probability of <0.05 were considered to be statistically significant. Figure 1 (Table I) .
Results
Testosterone and DHT concentrations were also measured in the tissue extracts. These measurements confirmed our earlier findings revealing significantly higher levels of testosterone in CaP (289.26 ± 76.9, n = 12) when compared to BPH (94.02 ± 14.4, n = 19) whilst DHT concentrations were significantly higher in BPH (201.64 ± 38.4) than in CaP tissue extracts (79.11 ± 27.8). The differences between the two groups were statistically significant (P<0.01).
Attempts to correlate the steroid hormone levels with the growth factor concentrations employing linear regression neoplastic human prostates. These findings are consistent with the reports on the production of EGF-related peptides in human prostate tissue (Gregory et al., 1987; Fowler et al., 1986) and TGFa-like molecules by prostate cancer cell lines (Connolly & Rose, 1989; MacDonald et al., 1990; Hofer et al., 1991) . TGFax was originally characterised by its ability to induce phenotypic transformation of normal cells (Sporn & Roberts, 1985) and the elevated expression of this growth factor in transformed cells has been reported (Marquardt et al., 1983) . However, TGFa has since been found also in a variety of other normal as well as neoplastic tissues (Coffey et al., 1987; Gomella et al., 1989; Lloyd et al., 1992) , suggesting a possible role for this growth factor in normal cell physiology.
The expression of TGFx in human benign prostate tissue has not previously been reported. In the current study, the TGFa concentrations in BPH were compatible with those measured in other tissues (Liu et al., 1990) . It was also of interest to note that there was no difference in the TGFa levels between BPH and prostate cancers even though there was a marginal increase in TGFo expression as the tumour became less differentiated. Significantly however, this increase in TGFa concentrations was manifested at a time when the expression of the EGF-receptor is down regulated (Maddy et al., 1989) thus raising further the possibility that TGFa may be excerting its biological effects by interacting with receptor sites other than those associated with EGF (Winkler et al., 1989) . Although one should not exclude the possibility that higher levels of EGF-R activation can also result in more rapid receptor turnover and/or down regulation of receptor expression.
Until recently TGFa was thought to be the counterpart of EGF in cancer, produced by the neoplastic prostate cell at the expense of EGF as part of an autocrine regulatory mechanism to reduce the need of these cells for exogenous mitogens (MacDonald et al., 1990; Hofer et al., 1991) . However the presence of immunoreactive EGF in extracts from BPH and cancer at equivalent concentrations highlights, once more, the complexity of the biological actions of these two growth factors in the human prostate. Additionally, the close association found between TGFx and EGF in the two tissue types suggests that the mechanism responsible for the secretion of one of these growth factors may also be responsible for controlling the production of the other. Whether both growth factors act in synergy to induce neoplastic transformation in the human prostate still remains to be clarified. In view of the increasing interest in the role of growth factors in endocrine related tumours Lai et al., 1989; MacDonald & Habib, 1992; Perheentupa et al., 1984) attempts were also made to establish the relationship between steroid hormone concentrations and the growth factors in the prostate extracts. Whilst there was some correlation between testosterone and TGFa and EGF in prostate cancer, the absence of a parallel association in BPH where DHT is the active steroid may possibly suggest an indirect role for testosterone in the regulation of prostatic EGF and TGF&c.
Though this relationship will need to be confirmed in a more dynamic system, the production of growth factors in some tissues has been shown to be sensitive to sex hormones. This has been witnessed in a number of systems including the submaxillary gland where testosterone increases EGF levels (Perheentupa et al., 1984) , in various human cancer cell lines where oestradiol influences the production of EGF related polypeptides and in breast cyst fluid where androgens modulate EGF concentrations (Lai et al., 1989) .
